Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
40 results about "HER2 Positive Breast Cancer" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells. In about 1 of every 5 breast cancers, the cancer cells have a gene mutation that makes an excess of the HER2 protein.
Methods of treating her2-positive cancer
InactiveUS20180251557A1The dosage is easy to controlEnable patient complianceOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsHER2 Positive Breast CancerClinical settings
Methods of treating patients having HER2-positive cancer are provided. Certain methods involve treatment of HER2 positive breast cancer using a programmed cell death protein 1 (PD-1) binding antagonist or a programmed death ligand 1 (PD-L1) binding antagonist in combination with trastuzumab and pertuzumab or with trastuzumab emtansine. The treatment regimen may be used in various clinical settings, for example, for treatment in the neoadjuvant or metastatic setting.
Owner:GENENTECH INC
Real-time fluorescent quantitative PCR (polymerase chain reaction) detection method as well as standard substance and detection kit for real-time fluorescent quantitative PCR detection
InactiveCN106399555AImprove reliabilityCorrect amplification statusMicrobiological testing/measurementReference genesPositive control
The invention discloses a real-time fluorescent quantitative PCR (polymerase chain reaction) detection method as well as a standard substance and a detection kit for real-time fluorescent quantitative PCR detection. The special standard substance is used for drawing standard curves, real-time fluorescent quantitative PCR detection is performed on an HER2 gene of a to-be-detected sample and a reference gene, and the detection method is used for clinical targeted therapy of breast cancer and stomach cancer. The invention further provides a plasmid vector containing a reference gene segment and a to-be-detected target gene segment in an equal proportion and taken as the detection standard substance. The invention also provides the real-time fluorescent quantitative PCR kit for detecting the amplification state of the HER2 gene. The kit comprises a PCR reaction system for detecting the amplification state of the HER2 gene, the standard substance and negative and positive controls. The detection method and the detection kit have the advantages of being convenient to use, high in detection efficiency, cost-saving and the like. Great significance in diagnosis of HER2 positive breast cancer as well as research and development, quality control and clinical application of breast cancer resistant drugs is realized.
Owner:上海康派尼恩医疗科技有限公司
HER2 nucleic acid aptamer and application thereof
ActiveCN105087593AGenetic material ingredientsMicrobiological testing/measurementAptamerHER2 Positive Breast Cancer
The invention relates to a nucleic acid aptamer specifically combined with HER2 polypeptide or HER2 positive tumor cells. Group modifying can be performed at two ends of the aptamer, group refers to one or multiple of amino, carboxyl, thiol, fluorescent molecule, cholesterol or polyethylene glycol, the base of the aptamer can be modified freely, and modifying refers to modifying one or multiple of sulfo, amino, fluoro, methoxyl or carboxyl. The invention further relates to application of the nucleic acid aptamer in preparing preparations used for detecting and / or treating HER2 positive breast cancer. The preparations can selectively combine with HER2 positive breast cancer cells while being weak in combination with HER2 negative breast cancer cells.
Owner:THE INST OF BASIC MEDICAL SCI OF CHINESE ACAD OF MEDICAL SCI
Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
InactiveUS20160175438A1Prolong progression-free survivalReduce riskOrganic active ingredientsAntibody ingredientsHER2 Positive Breast CancerProgression-free survival
The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity; and treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag.
Owner:GENENTECH INC
PIK3CA Mutation Status and SASH1 Expression Predicts Synergy Between Lapatinib and an AKT Inhibitor in HER2 Positive Breast Cancer
InactiveUS20130331405A1Improve expression levelOrganic active ingredientsBiocideProtein proteinHER2 Positive Breast Cancer
Methods for identifying a cancer patient, such as a breast cancer patient, suitable for treatment with a 4-anilinoquinazoline kinase inhibitor, such as lapatinib, and an AKT inhibitor, comprising detecting modulated expression of HER2 (ERBB2) and SASH1 or protein encoded thereof and detecting PIK3CA mutation status. High levels of expression in HER2 and high levels of SASH1 and / or positive PIK3CA mutation status indicate a patient that is suitable for treatment with a 4-anilinoquinazoline kinase inhibitor, such as lapatinib and an AKT inhibitor.
Owner:RGT UNIV OF CALIFORNIA
6,7-dialkoxy quinazoline derivatives and methods of treating drug resistant and other tumors
ActiveUS20110034459A1Superior anti-cancerSuperior anti-proliferative effectOrganic active ingredientsBiocideHER2 Positive Breast CancerCell growth
Compounds of formula (I)in which:R1 is:R2 is —CH3 or —CH2CH3; or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the compound of formula (I) and a pharmaceutically acceptable carrier. Processes for preparing the compound of formula (I).Methods of inhibiting a receptor tyrosine kinase in a subject in need thereof. Methods of inhibiting the growth of a tumor cell in a subject in need thereof. Methods of treating pancreatic cancer in a subject in need of treatment for pancreatic cancer. Methods of treating HER2 positive breast cancer in a subject in need of treatment for HER2 positive breast cancer. Methods of treating drug resistant non-small cell lung cancer in a subject in need of treatment for drug resistant non-small cell lung cancer. Each of these methods can include administering to the subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
Owner:NATCO PHARMA LTD
Shp2 phosphatase inhibitors and methods of use thereof
ActiveUS20190307745A1Inhibiting SHP phosphatase activityOrganic chemistryAntineoplastic agentsDiseaseHER2 Positive Breast Cancer
The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for suppressing tumor cell growth, ameliorating the pathogenesis of systemic lupus erythematosus, and the treatment of various other disorders, including Noonan syndrome, diabetes, neutropenia, neuroblastoma, melanoma, juvenile leukemia, juvenile myelomonocytic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, and other cancers associated with SHP2 deregulation with the compounds and compositions of the invention, alone or in combination with other treatments. Other cancers associated with SHP2 deregulation include HER2-positive breast cancer, triple-negative breast cancer, ductal carcinoma of the breast, invasive ductal carcinoma of the breast, non-small cell lung cancer, esophageal cancer, gastric cancer, squamous-cell carcinoma of the head and neck (SCCHN), and colon cancer.
Owner:D E SHAW RES & DEV LLC +1
A novel circulating tumor cell detecting method based on a chiral nanometer assembly
A novel circulating tumor cell detecting method based on a chiral nanometer assembly is provided and relates to the technical field of biological treatment. The method is characterized in that a circulating tumor cell is over-expressed in HER2 than normal cells, and a chiral Ag@Au core-shell nanometer particle assembly modified with an HER2 aptamer is utilized to achieve specific recognition of the circulating tumor cell. The method includes steps of preparing Ag@Au core-shell nanometer particles, preparing the chiral Ag@Au core-shell nanometer particle assembly modified with the HER2 aptamer, specifically recognizing and detecting HER2 positive breast cancer SK-BR-3 cells by utilizing a fact that dissociation occurs when the chiral Ag@Au core-shell nanometer particle assembly is brought into contact with HER2, and specifically recognizing and detecting the circulating tumor cell in a biological sample by utilizing the chiral Ag@Au core-shell nanometer particle assembly .
Owner:JIANGNAN UNIV
Radioactive complex targeting HER2 and preparation method and application of radioactive complex
ActiveCN110251695AEfficient targetingReduce radioactive concentrationPowder deliveryRadioactive preparation carriersHER2 Positive Breast CancerStructural formula
The invention provides a polypeptide compound with a HER2 targeting function. The polypeptide compound with the HER2 targeting function is formed by connecting a HER2 affinity with a bifunctional chelating agent through a polypeptide sequence; the polypeptide sequence is Met-Val-Lys; the general structural formula of the polypeptide compound is shown in formula (I) as shown in specification, wherein R is a HER2 affinity molecule and X is a bifunctional chelator group. The invention also provides a radiolabelled complex targeting HER2 by taking the polypeptide compound as a ligand. The radiolabeled complex provided by the invention can be used as a radioactive diagnostic probe for evaluating the HER2 receptor of breast cancer, and the probe can reduce the concentration of the kidney under the condition of keeping the uptake of the tumor unchanged, so that the target-to-non-target ratio of the tumor is improved, and the radiation dose to the kidney is reduced. The invention also provides a preparation method of the polypeptide compound and the radiolabelled complex, and application of the polypeptide compound and the radiolabelled complex in preparation of a HER2 positive breast cancer radioactive diagnosis and treatment probe for humans or animals.
Owner:SHANGHAI THERANOSTICS BIOTECH CO LTD
Fusion protein for treating breast cancer and application thereof
InactiveCN101585882AGenetic material ingredientsMacromolecular non-active ingredientsHER2 Positive Breast CancerMalignant phenotype
The present invention discloses a fusion protein for treating a breast cancer, wherein the fusion protein is Her2 single-chain fragment antibody-polypeptide, the Her2 single-chain fragment antibody is capable of targeting a Her2 receptor locating on a surface of a breast cancer cell, and the polypeptide is capable of carrying siRNA. The polypeptide includes a protamine polypeptide. The siRNA includes PLK1-siRNA, which is capable of restraining an expression of a knubble malignant phenotype gene. The fusion protein for treating the breast cancer is capable of carrying the PLK1-siRNA, and targeting and importing a Her2 positive breast cancer cell specifically, so as to bring the medicament into the cell. The treatment of the breast cancer is capable of generating a strong effect for restraining the breast cancer growth and transfer, may break a gene suppression effect of the existing antisense oligonucleotide and ribozyme, and becames a novel anti-Her2 gene medicament for treating the breast cancer.
Owner:SUN YAT SEN UNIV +2
Trastuzumab bond-linking gold nanorod compound, preparation method and application thereof in diagnosis and treatment of HER2 positive breast cancer
ActiveCN105597098AImprove performanceStrong penetrating powerHeavy metal active ingredientsEnergy modified materialsHER2 Positive Breast CancerFluorescence
The invention discloses a trastuzumab bond-linking gold nanorod compound, a preparation method and application thereof in the diagnosis and treatment of HER2 positive breast cancer, which overcome the defects of poor regulation of photo-thermal conversion efficiency and incapability of location of targeting gold nanoparticles. The preparation method comprises the following steps: firstly, preparing a gold nanorod with a certain length-diameter ratio, wherein the longitudinal absorption peak is 650 to 850nm, and the nanorod is capable of meeting the optimal optical wavelength penetrating through tissue of a human body; then connecting cysteine with porphyrinfluorescent molecules, next, through the action of an Au-S bond, bond-linking the gold nanorod with a cysteine-porphyrin compound, finally through a glutaraldehyde chemical crosslinking method, bond-linking a gold nanorod-cysteine-porphyrin compound with a drug trastuzumab. The obtained trastuzumab bond-linking gold nanorod compound is capable of showing in-situ or micro metastatic focus, and performing a targeting photo-thermal therapy on a detected tumor focus, so that the difficult problem of drug resistance of tumor can be effectively solved.
Owner:HARBIN MEDICAL UNIVERSITY
Methods of treating her2-positive cancer
InactiveUS20210040216A1Organic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsHER2 Positive Breast CancerProgrammed death
Owner:GENENTECH INC
Method of treating her2-positive breast cancers with selective androgen receptor modulators (SARMS)
This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, palbociclib (Ibrance), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; and / or HER2-positive; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
Owner:UNIV OF TENNESSEE RES FOUND
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
ActiveUS10258596B2MicrocapsulesNitrile/isonitrile active ingredientsToremifeneHER2 Positive Breast Cancer
Owner:UNIV OF TENNESSEE RES FOUND
Trastuzumab-mediated cis-platinum targeting conjugate and preparation method thereof
InactiveCN104857523ASimple preparation processImprove stabilityHeavy metal active ingredientsAntibody ingredientsHER2 Positive Breast CancerCarboxyl radical
The invention relates to medicine technical field, and particularly relates to a preparation method of a trastuzumab-mediated cis-platinum targeting conjugate and application of the trastuzumab-mediated cis-platinum targeting conjugate in the preparation of a breast cancer resistant drug. Amphiphilic block copolymer methoxy polyethylene glycol-polyglutamic acid (mPEG-PGA) prepared from methoxypolyethylene glycol amine and 5-benzyl L-glutamate N-carboxyanhydrie is used as a base material for preparation of cis-platinum loading nano balls through the membrane dialysis method, and a carrier is connected with trastuzumab by carrier surface carboxyl group to prepare the trastuzumab-mediated cis-platinum targeting conjugate. The trastuzumab-mediated cis-platinum targeting conjugate can be targeted to enrich chemotherapy drugs in tumor site so as to directly kill tumor cells, reduce the side and toxic effects of traditional antitumor drugs, and trastuzumab targeting therapy of HER2 positive breast cancer patients can be implemented. The trastuzumab-mediated cis-platinum targeting conjugate can cleverly realize trastuzumab and cis-platinum combined targeted drug delivery way, and has good application prospect in treatment of breast cancer by combination of trastuzumab and chemotherapy.
Owner:SOUTHEAST UNIV
Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
InactiveUS20140341893A1Improve treatment outcomesProlonged progression-free survivalOrganic active ingredientsBiological material analysisHER2 Positive Breast CancerChemotherapy regimen
The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of VEGFA and / or VEGFR2 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer. The present invention also provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of VEGFA and / or VEGFR2 relative to control levels in patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer.
Owner:GENENTECH INC
Breast cancer prognosis marker and application
PendingCN112592977AImprove the detection rateLow costMicrobiological testing/measurementDNA/RNA fragmentationCpG siteHER2 Positive Breast Cancer
The invention discloses a breast cancer prognosis evaluating marker and application, and belongs to the technical field of biology. The invention aims to find a marker for effectively evaluating breast cancer prognosis. TCGA, GEO and DNA methylation data of the whole genome level autonomously generated based on a sequencing technology are integrated, it is revealed that the tumor center is in a hypoxic state compared with the tumor edge, survival analysis finds that the HR of a CpG site cg15190451 is smaller than 1, it shows that the breast cancer progress risk is reduced along with increase of the methylation level, and the higher the level is, the patient prognosis is better; and it is prompted that the breast cancer prognosis effect can be judged according to the methylation level of the gene SLC16A5 where cg15190451 is located. The breast cancer prognostic marker is obtained by verifying hypoxia markers in an HER2 positive breast cancer sample on the basis of the expression level of SLC16A5, the breast cancer prognostic evaluation efficiency can be improved, the cost is saved, and the marker is suitable for popularization and application and has a good application prospect.
Owner:HARBIN INST OF TECH
A kind of her2 nucleic acid aptamer and its application
ActiveCN105087593BMicrobiological testing/measurementGenetic material ingredientsHER2 Positive Breast CancerFluorescence
Owner:THE INST OF BASIC MEDICAL SCI OF CHINESE ACAD OF MEDICAL SCI
6,7-dialkoxy quinazoline derivatives and methods of treating drug resistant and other tumors
Compounds of formula (I)in which:R1 is:R2 is —CH3 or —CH2CH3; or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the compound of formula (I) and a pharmaceutically acceptable carrier. Processes for preparing the compound of formula (I).Methods of inhibiting a receptor tyrosine kinase in a subject in need thereof. Methods of inhibiting the growth of a tumor cell in a subject in need thereof. Methods of treating pancreatic cancer in a subject in need of treatment for pancreatic cancer. Methods of treating HER2 positive breast cancer in a subject in need of treatment for HER2 positive breast cancer. Methods of treating drug resistant non-small cell lung cancer in a subject in need of treatment for drug resistant non-small cell lung cancer. Each of these methods can include administering to the subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
Owner:NATCO PHARMA LTD
Application of aspirin and herceptin combination or synergy in oncotherapy
ActiveCN107349426AGood curative effectPrevent proliferationOrganic active ingredientsAntibody ingredientsAspirinHER2 Positive Breast Cancer
The invention discloses application of aspirin and herceptin combination or synergy in oncotherapy, and relates to the technical field of oncotherapy. Relative to alone using of herceptin, aspirin is combined with the herceptin for medication, proliferation of HER2 positive tumor cells can be obviously restrained, and apoptosis of the HER2 positive tumor cells is promoted; and effect of anti-HER2 positive tumor of aspirin and herceptin combination for medication is better than effect of alone using of the herceptin. According to the application of aspirin and herceptin combination or synergy in oncotherapy, new application of the aspirin is discovered for the first time, and the aspirin helps to increase curative effect of the herceptin; and through the application of aspirin and herceptin combination or synergy in preparation of medicines used for treating tumors, theoretical basis is not only provided for anticancer effect of the aspirin in HER2 positive tumors, meanwhile, but also a new idea and a treatment mean are provided for treatment of tumors, especially HER2 positive tumors such as HER2 positive breast cancer or HER2 positive gastric cancer.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
HER2 aptamer-anticancer drug complex for cancer cell chemotherapy
ActiveUS20180050110A1Prevents release of drugEfficient killingOrganic active ingredientsSpecial deliveryHER2 Positive Breast CancerCancer cell
This invention relates to a complex for cancer cell chemotherapy and, more particularly, to a HER2 aptamer-anticancer drug complex for chemotherapy of cancer cells, which includes a nucleic acid aptamer specifically binding to HER2 and an anticancer drug linked with the nucleic acid aptamer, so that HER2-positive breast cancer cells are selectively targeted and killed.
Owner:KOREA UNIV RES & BUSINESS FOUND
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, palbociclib (Ibrance), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; and / or HER2-positive; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
Owner:UNIV OF TENNESSEE RES FOUND
Protein D and HER2 fusion protein and preparing method and application thereof
InactiveCN105254767APrevent proliferationSlow growth ratePeptide/protein ingredientsDepsipeptidesAdjuvantHER2 Positive Breast Cancer
The invention provides fusion protein. The fusion protein is formed by connecting adjuvant protein with the end N or the end C of a tumor-associated antigen through a linker or a direct connecting mode. The adjuvant protein contains Haemophilus influenzae (Hi) protein D or a segment of the Haemophilus influenzae (Hi) protein D; the tumor-associated antigen contains HER2 protein with the amino acid sequence being SEQ ID NO:3 or a segment of the HER2 protein. The invention further provides a preparing method for the fusion protein and application thereof. The prepared recombined protein can restrain proliferation of HER2 positive breast cancer cells in a Blab / c mice body, or delay the increase speed of breast tumors.
Owner:重庆科润生物医药研发有限公司
HER2 gene detection kit and application thereof
InactiveCN109943634AImprove reliabilityGood repeatabilityMicrobiological testing/measurementDiseaseReference genes
The invention discloses an HER2 gene detection kit and application thereof and particularly discloses a quantitative HER2 gene detection kit. The kit comprises a PCR reaction buffer solution, a Taq enzyme, a dNTP mixed solution, a standard substance with a gene segment of HER2 mesh and a Fas reference gene segment, a target gene specific primer and a fluorescence probe, a reference gene specific primer and a fluorescence probe and negative control and positive control. A detection method and the detection kit have the advantages that the kit is convenient to use and high in detection efficiency, and the method and the kit have important significance on diagnosis of the HER2 positive breast cancer and research and development, quality control and clinical application of drugs for resistingthe diseases.
Owner:SHANGHAI NAT ENG RES CENT OF ANTIBODY MEDICINE
Application of RNA m6A methylation detection reagent in preparation of product for predicting breast cancer anti-HER2 treatment effect
PendingCN114774548AIncreased drug resistanceGood clinical predictive valueMicrobiological testing/measurementHER2 Positive Breast CancerTreatment effect
The invention discloses application of an RNA m6A methylation detection reagent in preparation of a product for predicting a breast cancer anti-HER2 treatment effect. It is found for the first time that the m6A methylation modification level of HER2 positive breast cancer fresh tissue RNA has a good clinical prediction value for the breast cancer anti-HER2 treatment effect. If the methylation level of RNA m6A is high, the breast cancer anti-HER2 treatment sensitivity is high; if the methylation level of RNA m6A is low, the breast cancer anti-HER2 treatment sensitivity is low. Whether the methylation level of RNA m6A in fresh tissues of a breast cancer patient is changed or not is detected, so that the sensitivity condition of the patient on the anti-HER2 drug is predicted. The invention provides a new treatment and prognosis prediction target for breast cancer anti-HER2 treatment, and provides a new target for improving breast cancer anti-HER2 drug resistance.
Owner:SUN YAT SEN UNIV CANCER CENT
Application of combination or synergy of aspirin and trastuzumab in tumor therapy
ActiveCN107349426BGood curative effectPrevent proliferationOrganic active ingredientsAntibody ingredientsAspirinHER2 Positive Breast Cancer
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
InactiveCN104067128AOrganic active ingredientsBiological material analysisHER2 Positive Breast CancerChemotherapy combinations
The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin TM ) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of VEGFA and / or VEGFR2 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer. The present invention also provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin TM ) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of VEGFA and / or VEGFR2 relative to control levels in patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer.
Owner:F HOFFMANN LA ROCHE & CO AG
A trastuzumab-linked gold nanorod complex, its preparation method, and its application in the diagnosis and treatment of HER2-positive breast cancer
ActiveCN105597098BImprove performanceStrong penetrating powerHeavy metal active ingredientsEnergy modified materialsHER2 Positive Breast CancerFluorescence
The invention discloses a trastuzumab bond-linking gold nanorod compound, a preparation method and application thereof in the diagnosis and treatment of HER2 positive breast cancer, which overcome the defects of poor regulation of photo-thermal conversion efficiency and incapability of location of targeting gold nanoparticles. The preparation method comprises the following steps: firstly, preparing a gold nanorod with a certain length-diameter ratio, wherein the longitudinal absorption peak is 650 to 850nm, and the nanorod is capable of meeting the optimal optical wavelength penetrating through tissue of a human body; then connecting cysteine with porphyrinfluorescent molecules, next, through the action of an Au-S bond, bond-linking the gold nanorod with a cysteine-porphyrin compound, finally through a glutaraldehyde chemical crosslinking method, bond-linking a gold nanorod-cysteine-porphyrin compound with a drug trastuzumab. The obtained trastuzumab bond-linking gold nanorod compound is capable of showing in-situ or micro metastatic focus, and performing a targeting photo-thermal therapy on a detected tumor focus, so that the difficult problem of drug resistance of tumor can be effectively solved.
Owner:HARBIN MEDICAL UNIVERSITY
HER2 aptamer-anticancer drug complex for cancer cell chemotherapy
ActiveUS9950070B2Efficient killingEfficient deliveryOrganic active ingredientsSpecial deliveryAptamerHER2 Positive Breast Cancer
This invention relates to a complex for cancer cell chemotherapy and, more particularly, to a HER2 aptamer-anticancer drug complex for chemotherapy of cancer cells, which includes a nucleic acid aptamer specifically binding to HER2 and an anticancer drug linked with the nucleic acid aptamer, so that HER2-positive breast cancer cells are selectively targeted and killed.
Owner:KOREA UNIV RES & BUSINESS FOUND
Molecular marker for early screening of breast cancer and application thereof
ActiveCN111766386AIncreased sensitivityImprove accuracySerum immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsLuminal bAntigen
The invention relates to a molecular marker for early screening of a breast cancer. The molecular marker is a phosphorylated antigen fragment, a sequence of the molecular marker is shown as SEQ ID NO.1, and serine residues in the antigen are phosphorylated residues. The breast cancer comprises Luminal A, Luminal B, a HER2 positive breast cancer and a triple negative breast cancer. The invention also relates to a detection reagent capable of identifying the molecular marker and a detection kit containing the detection reagent.
Owner:南京凯弗生物技术有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com